Before the era of HER2-directed therapy, HER2 gene amplification was known to be otherwise associated with shorter disease-free and overall survival in breast cancers, as per a 1987 study conducted by Slamon et al. [44]. The gene discussed is ERBB2; the disease is breast carcinoma.